Jan Joseph Melenhorst

List of Publications by Year in Descending Order

199 papers	16,515 citations	52 h-index	127 g-index
221 ext. papers	20,825 ext. citations	6.8 avg, IF	6.13 L-index

#	Paper	IF	Citations
199	Decade-long leukaemia remissions with persistence of CD4 CAR T cells.. *Nature*, **2022**,	50.4	30
198	Next-generation CAR T cells to overcome current drawbacks. *International Journal of Hematology*, **2021**, 114, 532-543	2.3	2
197	Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19. *Blood*, **2021**, 138, 167-167	2.2	0
196	Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells. *Blood*, **2021**, 138, 166-166	2.2	0
195	Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report. *Annals of the New York Academy of Sciences*, **2021**,	6.5	1
194	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. *British Journal of Haematology*, **2021**, 193, 851-855	4.5	0
193	Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor-T Cell Therapy. *Cancer Journal (Sudbury, Mass)*, **2021**, 27, 151-158	2.2	
192	CT103A, a forward step in multiple myeloma immunotherapies.. *Blood Science*, **2021**, 3, 59-61	0.9	1
191	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. *Frontiers in Oncology*, **2021**, 11, 669071	5.3	8
190	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells **2021**, 9,		6
189	High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies. *Current Hematologic Malignancy Reports*, **2021**, 16, 112-116	4.4	
188	Engineering enhanced CAR T-cells for improved cancer therapy. *Nature Cancer*, **2021**, 2, 780-793	15.4	6
187	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	6
186	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6580-6590	12.9	1
185	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 807-816		1
184	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.. *Frontiers of Medicine*, **2021**, 15, 783	12	
183	A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. *Blood*, **2020**, 135, 505-509	2.2	15

182	CAR-T and ibrutinib vs CLL: sequential or simultaneous?. *Blood*, **2020**, 135, 1611-1612	2.2	3
181	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. *Blood*, **2020**, 136, 1980-1983	2.2	7
180	CRISPR-engineered T cells in patients with refractory cancer. *Science*, **2020**, 367,	33.3	448
179	Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis. *Critical Care Medicine*, **2020**, 48, 344-352	1.4	11
178	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. *Clinical and Experimental Medicine*, **2020**, 20, 469-480	4.9	5
177	B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent. *Blood*, **2020**, 136, 44-44	2.2	1
176	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *Journal of Clinical Investigation*, **2020**, 130, 673-685	15.9	45
175	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. *Blood*, **2020**, 136, 30-32	2.2	1
174	A phase I clinical trial of PSMA-directed/TGF□nsensitive CAR-T cells in metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, TPS269-TPS269	2.2	2
173	Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome **2020**, 2, e0295		2
172	Mechanisms of resistance to CAR T cell therapies. *Seminars in Cancer Biology*, **2020**, 65, 91-98	12.7	11
171	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. *Signal Transduction and Targeted Therapy*, **2020**, 5, 134	21	36
170	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. *Molecular Therapy*, **2020**, 28, 2367-2378	11.7	13
169	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. *Blood Advances*, **2020**, 4, 5174-5183	7.8	10
168	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 2862-2871	2.2	45
167	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. *Methods in Molecular Biology*, **2020**, 2121, 213-239	1.4	7
166	Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 8, 656-658.e6	7.9	6
165	iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. *Genome Biology*, **2019**, 20, 14	18.3	20

164	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy. *Blood*, **2019**, 134, 44-58	2.2	69
163	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. *Molecular Therapy*, **2019**, 27, 1919-1929	11.7	101
162	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *Journal of Clinical Investigation*, **2019**, 129, 2210-2221	15.9	312
161	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. *Blood*, **2019**, 134, 49-49	2.2	7
160	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. *Blood*, **2019**, 134, 1909-1909	2.2	3
159	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. *Blood*, **2019**, 134, 622-622	2.2	10
158	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 1863-1863	2.2	13
157	A phase I clinical trial of PSMA-directed/TGF□nsensitive CAR-T cells in metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, TPS347-TPS347	2.2	22
156	A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 681-681	2.2	2
155	Engineered T Cell Therapies from a Drug Development Viewpoint. *Engineering*, **2019**, 5, 140-149	9.7	7
154	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. *Blood Advances*, **2019**, 3, 2812-2815	7.8	61
153	Toward precision manufacturing of immunogene T-cell therapies. *Cytotherapy*, **2018**, 20, 623-638	4.8	11
152	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8 TCR-V□expansions. *Scientific Reports*, **2018**, 8, 2534	4.9	2
151	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*, **2018**, 24, 563-571	50.5	649
150	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology*, **2018**, 155, 29-32	13.3	209
149	Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. *Blood*, **2018**, 132, 1022-1026	2.2	38
148	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight*, **2018**, 3,	9.9	250
147	Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. *Cancer Immunology Research*, **2018**, 6, 1100-1109	12.5	105

146	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. *Blood*, **2018**, 132, 1886-1886	2.2	14
145	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. *Blood*, **2018**, 132, 298-298	2.2	61
144	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. *Blood*, **2018**, 132, 235-235	2.2	1
143	Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones. *Blood*, **2018**, 132, 699-699	2.2	3
142	Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. *Blood*, **2018**, 132, 4198-4198	2.2	51
141	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. *Blood*, **2018**, 132, 1973-1973	2.2	12
140	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). *Blood*, **2018**, 132, 1974-1974	2.2	9
139	Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL). *Blood*, **2018**, 132, 4548-4548	2.2	
138	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. *Molecular Therapy*, **2018**, 26, 269-279	11.7	63
137	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. *JCI Insight*, **2018**, 3,	9.9	90
136	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. *Frontiers in Immunology*, **2018**, 9, 2740	8.4	45
135	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. *OncoImmunology*, **2018**, 7, e1468956	7.2	60
134	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nature Medicine*, **2018**, 24, 1499-1503	50.5	286
133	Neurotoxicity after CTL019 in a pediatric and young adult cohort. *Annals of Neurology*, **2018**, 84, 537-546	9.4	49
132	Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. *Molecular Therapy*, **2018**, 26, 1855-1866	11.7	247
131	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature*, **2018**, 558, 307-312	42.4	362
130	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. *Critical Care Medicine*, **2017**, 45, e124-e131	1.4	261
129	PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood*, **2017**, 129, 1039-1041	2.2	285

128	Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. *Blood*, **2017**, 130, 2569-2572	2.2	65
127	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. *Blood*, **2017**, 130, 2317-2325	2.2	180
126	Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL). *Cytotherapy*, **2017**, 19, S118-S119	4.8	4
125	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Science Translational Medicine*, **2017**, 9,	17.5	697
124	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *New England Journal of Medicine*, **2017**, 377, 2545-2554	59.2	951
123	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. *Cancer Immunology Research*, **2017**, 5, 1152-1161	12.5	181
122	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. *Leukemia*, **2017**, 31, 246-248	10.7	73
121	The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. *Journal of Clinical Oncology*, **2017**, 35, 103-103	2.2	65
120	Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).. *Journal of Clinical Oncology*, **2017**, 35, 10507-10507	2.2	9
119	Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer.. *Journal of Clinical Oncology*, **2017**, 35, 3011-3011	2.2	3
118	CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.. *Journal of Clinical Oncology*, **2017**, 35, 7509-7509	2.2	27
117	Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL.. *Journal of Clinical Oncology*, **2017**, 35, 137-137	2.2	1
116	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. *Blood*, **2017**, 130, 807-807	2.2	4
115	Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer. *Current Drug Targets*, **2017**, 18, 332-340	3	
114	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. *Blood*, **2016**, 128, 360-70	2.2	143
113	Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma **2016**,		2
112	Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy. *Blood*, **2016**, 128, 1100-1100	2.2	15
111	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. *Blood*, **2016**, 128, 1147-1147	2.2	53

110	Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. *Blood*, **2016**, 128, 2159-2159	2.2	8
109	Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 217-217	2.2	46
108	Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia. *Blood*, **2016**, 128, 220-220	2.2	4
107	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. *Blood*, **2016**, 128, 281-281	2.2	11
106	Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL). *Blood*, **2016**, 128, 2812-2812	2.2	4
105	Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas. *Blood*, **2016**, 128, 3026-3026	2.2	15
104	Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control. *Blood*, **2016**, 128, 4549-4549	2.2	2
103	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 57-57	2.2	14
102	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. *Blood*, **2016**, 128, 5702-5702	2.2	23
101	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. *Blood*, **2016**, 128, 652-652	2.2	24
100	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. *Blood*, **2016**, 128, 974-974	2.2	27
99	Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.. *Journal of Clinical Oncology*, **2016**, 34, 2067-2067	2.2	14
98	Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.. *Journal of Clinical Oncology*, **2016**, 34, 3007-3007	2.2	17
97	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.. *Journal of Clinical Oncology*, **2016**, 34, 3009-3009	2.2	19
96	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. *Journal of Clinical Oncology*, **2016**, 34, 3011-3011	2.2	74
95	Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5511-5511	2.2	21
94	Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).. *Journal of Clinical Oncology*, **2016**, 34, 7002-7002	2.2	31
93	Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).. *Journal of Clinical Oncology*, **2016**, 34, 7564-7564	2.2	7

92	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *Journal of Clinical Investigation*, **2016**, 126, 3814-3826	15.9	352
91	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *Journal of Immunological Methods*, **2016**, 434, 1-8	2.5	108
90	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. *Cancer Discovery*, **2016**, 6, 664-79	24.4	603
89	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood*, **2016**, 127, 1117-27	2.2	282
88	Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. *Journal of the American Academy of Dermatology*, **2016**, 75, 1054-1057	4.5	12
87	CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. *Science Translational Medicine*, **2015**, 7, 285ra63	17.5	78
86	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science Translational Medicine*, **2015**, 7, 303ra139	17.5	1071
85	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. *Cancer Discovery*, **2015**, 5, 1282-95	24.4	713
84	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 1040-7	59.2	417
83	Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. *Molecular Therapy*, **2015**, 23, 179-83	11.7	21
82	Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells **2015**, 3,		2
81	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. *Neuro-Oncology*, **2015**, 17, v110.4-v111	1	9
80	Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. *Stem Cell Research*, **2015**, 14, 95-104	1.6	41
79	Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL). *Blood*, **2015**, 126, 1334-1334	2.2	3
78	Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. *Blood*, **2015**, 126, 183-183	2.2	55
77	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. *Blood*, **2015**, 126, 2523-2523	2.2	5
76	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. *Blood*, **2015**, 126, 3769-3769	2.2	34
75	Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019). *Blood*, **2015**, 126, 681-681	2.2	94

74	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. *Blood*, **2015**, 126, 683-683	2.2	15
73	Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.. *Journal of Clinical Oncology*, **2015**, 33, 3007-3007	2.2	28
72	Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. *Stem Cells*, **2014**, 32, 1278-88	5.8	67
71	Chimeric antigen receptor T cells for sustained remissions in leukemia. *New England Journal of Medicine*, **2014**, 371, 1507-17	59.2	3305
70	Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells. *Cytotherapy*, **2014**, 16, 135-46	4.8	4
69	Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. *Molecular Therapy*, **2014**, 22, 1388-1395	11.7	80
68	Timing and intensity of exposure to interferon-□critically determines the function of monocyte-derived dendritic cells. *Immunology*, **2014**, 143, 96-108	7.8	10
67	Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL. *Blood*, **2014**, 124, 1982-1982	2.2	32
66	Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. *Blood*, **2014**, 124, 1983-1983	2.2	6
65	Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. *Blood*, **2014**, 124, 2296-2296	2.2	34
64	Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. *Blood*, **2014**, 124, 3087-3087	2.2	9
63	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. *Blood*, **2014**, 124, 380-380	2.2	12
62	Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. *Blood*, **2014**, 124, 966-966	2.2	4
61	Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy. *Blood*, **2014**, 124, 1110-1110	2.2	
60	Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells. *Blood*, **2014**, 124, 2439-2439	2.2	
59	Regulatory T cells from another bench: ready for the bedside?. *Cytotherapy*, **2013**, 15, 1183-4	4.8	
58	When one is better than two. *Cytotherapy*, **2013**, 15, 139	4.8	
57	Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant. *Haematologica*, **2013**, 98, 346-52	6.6	19

56	Innovation and opportunity for chimeric antigen receptor targeted T cells. *Cytotherapy*, **2013**, 15, 1046-52	4.8	7
55	Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. *Leukemia*, **2013**, 27, 1538-47	10.7	80
54	Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. *Blood*, **2013**, 122, 163-163	2.2	20
53	High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function. *Blood*, **2013**, 122, 2567-2567	2.2	1
52	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. *Blood*, **2013**, 122, 3885-3885	2.2	3
51	Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival. *Blood*, **2013**, 122, 3282-3282	2.2	
50	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. *Blood*, **2013**, 122, 3705-3705	2.2	
49	KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. *Blood*, **2012**, 119, 1511-21	2.2	35
48	Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. *Blood*, **2012**, 119, 368-76	2.2	23
47	LGL: a disease rediscovered. *Blood*, **2012**, 120, 2932-3	2.2	2
46	Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. *Haematologica*, **2012**, 97, 867-73	6.6	25
45	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. *Blood*, **2012**, 120, 3283-3283	2.2	1
44	Long Term Maintenance of Myeloid Leukemia Stem Cell-Like Populations Cultured with Mesenchymal Stromal Cells (MSC). *Blood*, **2012**, 120, 3546-3546	2.2	
43	Improved Strategy for Rapid Generation of Quadrivirus-Specific CD8+ and CD4+ Cytotoxic T Lymphocytes (CTLs) for Adoptive Transfer After Stem Cell Transplantation (SCT). *Blood*, **2012**, 120, 4121-4121	2.2	
42	Abrogation of Myeloid Derived Suppressor Cell-Like Inhibitory Activity of K562 Restores Antigen Presenting Cell Functions. *Blood*, **2012**, 120, 4118-4118	2.2	
41	Tumor vaccines and beyond. *Cytotherapy*, **2011**, 13, 8-18	4.8	7
40	Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. *Blood*, **2011**, 117, 5250-6	2.2	12
39	Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 800-9	4.7	22

38	Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1846-54	4.7	25
37	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. *Blood*, **2011**, 117, 2691-9	2.2	64
36	Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. *Journal of Immunology*, **2011**, 187, 2824-33	5.3	31
35	Is human cell therapy research caught in a mousetrap?. *Molecular Therapy*, **2011**, 19, 224-7	11.7	6
34	Low Thymic Natural Regulatory T Cell Output in the Donor Is Associated with An Increased Incidence of Extensive Chronic GvHD After T Cell Depleted Matched Sibling Stem Cell Transplantation (SCT). *Blood*, **2011**, 118, 328-328	2.2	
33	KIT with D816 Mutations Cooperates with CBFB-MYH11 for Leukemogenesis in Mice. *Blood*, **2011**, 118, 867-867	2.2	
32	Minor histocompatibility antigen discovery: turning up the HEATR. *Blood*, **2010**, 115, 4630-1	2.2	3
31	Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. *Blood*, **2010**, 116, 4700-2	2.2	148
30	Evolution of the Donor T Cell Repertoire In Allogeneic Stem Cell Transplant Recipients In the Second Decade After Transplantation. *Blood*, **2010**, 116, 831-831	2.2	
29	Engineering of Human T-Cells with a Novel Aurora-A Kinase-Specific T-Cell Receptor Gene Transfer Confers Anti-Leukemia Reactivity. *Blood*, **2010**, 116, 4290-4290	2.2	
28	Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. *Journal of Immunology*, **2009**, 183, 1120-32	5.3	88
27	Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. *Journal of Immunological Methods*, **2009**, 340, 11-24	2.5	119
26	Optimizing T-cell expansion: have we reached the limit?. *Cytotherapy*, **2009**, 11, 813-4	4.8	1
25	High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. *Blood*, **2009**, 113, 2238-44	2.2	55
24	The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. *Blood*, **2009**, 114, 5071-80	2.2	72
23	Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity.. *Blood*, **2009**, 114, 4081-4081	2.2	
22	Both Nai ve and Memory T-Cell Subsets Participate in Alloresponses to HLA-Mismatched Targets Implications for Adoptive Transfer of Viral Antigen-Specific T Cells.. *Blood*, **2009**, 114, 2439-2439	2.2	1
21	Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. *Journal of Immunological Methods*, **2008**, 338, 31-9	2.5	30

20	Contribution of TCR-beta locus and HLA to the shape of the mature human Vbeta repertoire. *Journal of Immunology*, **2008**, 180, 6484-9	5.3	14
19	Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2008**, 73, 1001-9	4.6	41
18	Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies. *Blood*, **2008**, 112, 1173-1173	2.2	
17	The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. *Journal of Immunological Methods*, **2007**, 321, 107-20	2.5	21
16	Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.. *Blood*, **2007**, 110, 1807-1807	2.2	
15	Identification of a Shared CD4+ and CD8+ T Cell Epitope within Human Neutrophil Elastase for Peptide Vaccination in HLA-A02 Negative Leukemia Patients.. *Blood*, **2007**, 110, 1803-1803	2.2	
14	Peptide-Major Histocompatibility Complex Class I Tetramers with Enhanced Coreceptor Binding Properties Enable Visualization of Low Avidity Leukemia-Associated Antigen-Specific CD8+ T Cells.. *Blood*, **2007**, 110, 1343-1343	2.2	1
13	Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. *Journal of Immunotherapy*, **2006**, 29, 436-43; discussion 365-6	5	20
12	Widening the Applicability of Human Neutrophil Elastase and Proteinase 3 Peptide Vaccines by Elucidating Immunogenic Non-HLA-A2 MHC Class I Restricted Epitopes.. *Blood*, **2006**, 108, 3708-3708	2.2	1
11	In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. *Clinical Cancer Research*, **2005**, 11, 4495-503	12.9	82
10	Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. *Clinical Cancer Research*, **2004**, 10, 1047-56	12.9	18
9	The proliferation associated nuclear element (PANE1) is conserved between mammals and fish and preferentially expressed in activated lymphoid cells. *Gene Expression Patterns*, **2004**, 4, 389-95	1.5	15
8	Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. *Blood*, **2004**, 103, 4588-93	2.2	81
7	Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. *Blood*, **2003**, 101, 1752-8	2.2	93
6	Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. *Blood*, **2003**, 102, 2892-900	2.2	185
5	Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. *Blood*, **2003**, 102, 3786-92	2.2	17
4	T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. *The Hematology Journal*, **2003**, 4, 18-25		27
3	Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. *British Journal of Haematology*, **2002**, 119, 97-105	4.5	36

2	Large granular lymphocyte leukaemia is characterized by a clonal T-cell receptor rearrangement in both memory and effector CD8(+) lymphocyte populations. *British Journal of Haematology*, **2001**, 112, 189-94	4.5	36
1	Aplastic anaemia in donor cells 14 years after bone-marrow transplant. *Lancet, The*, **1999**, 353, 2037-8	40	6